[Ceftriaxone (Rocefin) in the treatment of bronchopulmonary infections].
Ceftriaxone, cephalosporin of the third generation, was given to 40 adults admitted to hospital for bronchopulmonary infections. Pneumonia and aggravation of chronic bronchitis were diagnosed in 27 and 13 patients, respectively. The drug was given in a single daily dose 1-2 g intravenously or intramuscularly. Mean duration of the treatment course was 6.13 days. High efficacy of the antibiotic ceftriaxone was observed in 38(95%) patients. One woman failed the treatment. She had pneumonia following polychemotherapy for advanced breast cancer. The drug tolerance was good. Only one allergic reaction occurred. The study of the sensitivity of 333 strains of the bacteria isolated from the sputum of 235 pulmonological patients showed that the absolute majority of the strains (98%) of both gram-positive and gram-negative microorganisms are suppressed by ceftriaxone. Thus, the conclusion is made on efficacy of ceftriaxone against bronchopulmonary infections. The drug is applicable both in hospitals and outpatiently.
Nonikov
V E
VE
Konstantinova
T D
TD
Makarova
O V
OV
Manziuk
E N
EN
Minaev
V I
VI
Ritchik
L A
LA
D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D001991:Bronchitis / Q000188:drug therapy* / Q000382:microbiology; D002443:Ceftriaxone / Q000494:pharmacology / Q000627:therapeutic use*; D002511:Cephalosporins / Q000494:pharmacology / Q000627:therapeutic use*; D002908:Chronic Disease; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D013183:Sputum / Q000382:microbiology; D013997:Time Factors
D002511:Cephalosporins; D002443:Ceftriaxone
Tseftriakson (rotsefin) pri lechenii bronkholegochnykh infektsiĭ.